CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast, ovarian, gastric and bladder, will be presented at the ESMO 2012 Congress (European Society for Medical Oncology ), Sept. 28 – Oct. 2 in Vienna, Austria. The medicines are some of the first therapies developed using Merrimack's proprietary scientific approach – Network Biology – focusing not on gene expression but on underlying cancer signals that trigger tumor growth.
"At Merrimack Pharmaceuticals, we believe the key to finding new treatment options for cancer is to start closer to the source of the problem – with signals in the cancer cell that turn specific processes on and off, triggering tumor growth and drug resistance," said Robert J. Mulroy, President and Chief Executive Officer, Merrimack Pharmaceuticals. "By charting and modeling these molecular pathways and signals, we can identify the most sensitive points from which to attack the cancer and then develop medicines and companion diagnostics to disrupt or slow tumor growth."
Therapy and Poster Overview:
About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Kathleen Petrozzelli Gallagher, Merrimack, 617-441-1043, email@example.com
Liz Bryan, Spectrum, 202-955-6222, firstname.lastname@example.org
|SOURCE Merrimack Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved